Skip Navigation

Europace 2001 3(3):233-240; doi:10.1053/eupc.2001.0168
© 2001 by European Society of Cardiology
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sheldon, R.
Right arrow Articles by Rose, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sheldon, R.
Right arrow Articles by Rose, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


SYNCOPE

Components of clinical trials for vasovagal syncope

R. Sheldon and S. Rose

Cardiovascular Research Group University of Calgary Calgary, Alberta, Canada

Abstract

The time is ripe for adequately powered, randomized, placebo-controlled clinical trials in vasovagal syncope. Vasovagal syncope is a common syndrome, the symptoms of which can be troublesomely frequent. It is usually diagnosed by tilt-table testing, although this has persistent problems with both sensitivity and specificity. Patients with syncope and positive tilt tests have been the subjects of numerous studies of natural history, risk stratification, and treatment. This paper discusses studies of treatments for vasovagal syncope in the context of a classification of the levels of evidence that can be gleaned from clinical studies. The reasons for placebo-controlled trials are reviewed, as is the evidence for various methods of risk stratification. Data for power calculations are presented for the primary outcome, the time to the first syncope recurrence. Strengths and weakness of the four main types of outcomes for clinical trials are compared.

Key Words: Vasovagal syncope, tilt-table test, randomized clinical trials, quality of life, cost utility, drug therapy, pacemaker therapy


Correspondence: Dr Robert Sheldon, Faculty of Medicine, University of Calgary, Health Sciences Centre, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada. E-mail: sheldon{at}ucalgary.ca


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
EuropaceHome page
Task Force members, M. Brignole, P. Vardas, E. Hoffman, H. Huikuri, A. Moya, R. Ricci, N. Sulke, W. Wieling, EHRA Scientific Documents Committee, et al.
Indications for the use of diagnostic implantable and external ECG loop recorders
Europace, May 1, 2009; 11(5): 671 - 687.
[Full Text] [PDF]


Home page
HeartHome page
S W Parry, N Steen, R S Bexton, M Tynan, and R A Kenny
Pacing in elderly recurrent fallers with carotid sinus hypersensitivity: a randomised, double-blind, placebo controlled crossover trial
Heart, March 1, 2009; 95(5): 405 - 409.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. Brignole, R. Sutton, C. Menozzi, R. Garcia-Civera, A. Moya, W. Wieling, D. Andresen, D. G. Benditt, P. Vardas, and for the International Study on Syncope of Uncertai
Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope
Eur. Heart J., May 1, 2006; 27(9): 1085 - 1092.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D. J. Farwell, N. Freemantle, and N. Sulke
The clinical impact of implantable loop recorders in patients with syncope
Eur. Heart J., February 1, 2006; 27(3): 351 - 356.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D.J. Farwell, N. Freemantle, and A.N. Sulke
Use of implantable loop recorders in the diagnosis and management of syncope
Eur. Heart J., July 2, 2004; 25(14): 1257 - 1263.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
F. Croci, M. Brignole, C. Menozzi, A. Solano, P. Donateo, D. Oddone, E. Puggioni, and G. Lolli
Efficacy and feasibility of isometric arm counter-pressure manoeuvres to abort impending vasovagal syncope during real life
Europace, January 1, 2004; 6(4): 287 - 291.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
R. Sheldon, S. Rose, S. Connolly, and on behalf of the POST investigators
Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope: Rationale and study design
Europace, January 1, 2003; 5(1): 71 - 75.
[Abstract] [PDF]


Home page
CirculationHome page
C.T. P. Krediet, N. van Dijk, M. Linzer, J. J. van Lieshout, and W. Wieling
Management of Vasovagal Syncope: Controlling or Aborting Faints by Leg Crossing and Muscle Tensing
Circulation, September 24, 2002; 106(13): 1684 - 1689.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.